People with non-small cell lung cancer (NSCLC) who also have pulmonary fibrosis and emphysema are at a greater risk of acute flares following cancer treatment that includes chemotherapy, surgery, or radiotherapy, a study from South Korea reports. The study “Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in…
News
Indalo Therapeutics announced that dosing has begun in the first patient enrolled in its Phase 1 trial assessing the safety, tolerability, and properties of IDL-2965, the company’s lead candidate to treat fibrotic diseases including idiopathic pulmonary fibrosis (IPF). IDL-2965 is an oral, selective antagonist of three types…
Veracyte announced new data further supporting its Envisia Genomic Classifier as a useful tool in helping doctors to diagnosis idiopathic pulmonary fibrosis (IPF) with greater confidence and without the need for surgery to biopsy lung…
Healthy and idiopathic pulmonary fibrosis (IPF) lung cells respond differently to transforming growth factor-beta 1 (TGF-beta 1) — a key mediator of fibrosis — both in terms of gene activity and DNA methylation, likely due to the fibrotic environment that IPF cells are exposed to in the lungs,…
No significant differences in survival rates, extending out 10 years, were found in idiopathic pulmonary fibrosis (IPF) patients given either a single- or double-lung transplant, a study reports. These findings, based on data cover more than 2,000 IPF patients who underwent either, suggest a bias in studies favoring a…
A positron emission tomography (PET) tracer that recognizes a potential protein biomarker of fibrotic interstitial lung diseases can be used to detect idiopathic pulmonary fibrosis (IPF) and several cancers in PET scans, a pilot clinical study suggests. The research, “Evaluation of integrin αvβ6 cystine knot PET tracers to…
Fast weight loss in people with idiopathic pulmonary fibrosis (IPF), even after lung transplant, is linked with worse prognosis, and may indicate immune system activation, a study suggests. People who experience greater weight loss over a short period may be at greater risk for poor outcomes. The research, “…
April Kloxin, PhD, has received the 2019 National Institutes of Health (NIH) Director’s New Innovator Award to develop next-generation materials and tools to help accelerate research on idiopathic pulmonary fibrosis (IPF). Kloxin, a professor at the University of Delaware, is one of 60 researchers across the U.S. to win…
Scientists have found the mechanism by which a new mutation in the surfactant protein A1 (SFTPA1) gene leads to the onset and progression of idiopathic pulmonary fibrosis (IPF) in mice. Their findings were described in the study, “A homozygous SFTPA1 mutation drives necroptosis of type II alveolar…
A Japanese agency has cleared MediciNova’s request for a patent covering the use of its orally available candidates MN-001 (tipelukast) and MN-002 — a major metabolite of MN-001 — in treating idiopathic pulmonary fibrosis (IPF). The company announced it has received a Notice of Allowance from…
